No abstract

Objectives: This review provides a detailed review of the treatment of obesity with natural products that are formulated as phytosomes. When novel drug delivery technology is used instead of traditional drug delivery in herbal medicine, side effects are reduced while safety and efficacy are improved.This article provides information about obesity along with its treatment and with special emphasis on phytosomes, their preparation and evaluation along with their application in obesity. Methods: A comprehensive search of electronic databases such as Medline, Embase, Cochrane Library, Google, and Google Patents was carried out. Results: This review explains the details of research done on phytosomes with special reference to anti-obesity drugs. Still, there is a need to formulate anti-obesity herbal drugs as phytosomes to get better bioavailability, and fewer side effects. This phytosomal drug delivery approach may resolve the problems associated with conventional drug delivery. Conclusion: Integrating herbal medicine with novel drug delivery systems such as phytosomes to combat obesity has a significant scope and importance.

The current research aims to formulate Venlafaxine Sustained Release (VHL-SR) tablets using hydrophilic-hydrophobic polymers combination blends by melt granulation technique which highlights the novelty. The polymers selected for the present study have matrix forming properties. Results of FTIR studies have shown that there were no interactions between the polymers used and the drug VHL. Various formulations of VHL- SR tablets (F1-F16) using different combinations of hydrophilic and hydrophobic polymers viz. Carbopol 71G, HPMC K15M, PEO, sodium CMC, Eudragit RS100 and precirol were formulated. Prior preformulation studies carried out on powder blend showed good flow properties. Routine quality evaluations of the VHL-SR tablets showed the diameter of the tablets of all formulations were found to be 9.0±0.0 mm and thickness ranged between 2.08±0.08 to 2.25±0.14 mm, hardness 4.08±0.20 - 5.50±0.31 kg/cm2 , percentage friability 0.24±0.03 - 0.45±0.01%, weight variation from 0-1.15%, drug content uniformity from 98.17±0.68 to 101.89±0.73%, all within Pharmacoepial limits. Results of in-vitro drug release study indicated that the formulation containing Carbopol 71G (50 mg), Xanthan gum (75 mg) and MCC (50 mg) extended the release of the VHL. Formulation F15 was the optimized one which gave satisfactory release (95.2%) for 16 hr and with a similarity factor (f2) 68.46, the release kinetics best explained by the Korsmeyer-peppas and Higuchi diffusion models. The “N” values between 0.5-1.0 in all the formulations exhibiting a non-Fickian release behavior controlled by a combination of diffusion and chain relaxation mechanism. The formulation showed appreciable stability under accelerated conditions after 2 m.

The present investigation was aimed at developing the stability indicating spectrophotometric methods for the determination of nelfinavir mesylate (NEM) in pharmaceutical dosage forms. The stability of NEM was tested in various dissolution media maintained at ambient temperature and 37 o C for 48 h. Stability studies of NEM in various media indicated that the drug was stable in 0.1M HCl and pH 7.8 phosphate buffer. The λmax were found 201.4 and 212.0 nm for 0.1M HCl and pH 7.8 phosphate buffers respectively with low coefficient of variation of < 5.11 %. The linearity of NEM was found in the range of 0.5 -60 µg/mL for 0.1M HCl and 0.5 -40 µg/mL for pH 7.8 phosphate buffer. The validated methods were applied to determine NEM concentration in formulations. In-vitro dissolution testing indicated that the NEM was stable and drug release was uniform from tablet dosage forms. The optimized media could be employed to study the dissolution profiles of NEM in bioequivalence studies.